MOFECON 250 CAPSULES 250 MG

Ülke: Singapur

Dil: İngilizce

Kaynak: HSA (Health Sciences Authority)

Aktif bileşen:

Mycophenolate Mofetil

Mevcut itibaren:

GOLDPLUS UNIVERSAL PTE LTD

ATC kodu:

L04AA06

Farmasötik formu:

CAPSULE

Kompozisyon:

Mycophenolate Mofetil 250 mg

Uygulama yolu:

ORAL

Reçete türü:

Prescription Only

Tarafından üretildi:

CONCORD BIOTECH LIMITED

Yetkilendirme durumu:

ACTIVE

Yetkilendirme tarihi:

2020-09-18

Ürün özellikleri

MOFECON
TM
VIMOF01-var (SIN)
DESCRIPTION
MOFECON
TM 250: White to off white granular powder filled in
size ‘1’ hard gelatin capsule with opaque blue cap imprinted
‘C3 250’ and opaque brown body.
MOFECON
TM
500:
Lavender-colored,
caplet-shaped,
film-coated tablet, debossed with “C4” on one side and plain
on the other side.
COMPOSITION
MOFECON
TM
250:
each
capsule
contains
mycophenolate
mofetil 250 mg.
_Excipients:_ Microcrystalline cellulose, hydroxypropyl cellulose,
povidone, croscarmellose sodium, talc, magnesium stearate.
MOFECON
TM 500: Each tablet contains mycophenolate mofetil
500 mg.
_Excipients:_
Microcrystalline
cellulose,
croscarmellose
sodium,
povidone,
magnesium
stearate,
hypromellose,
titanium dioxide, polyethylene glycol, iron oxide red, indigo
carmine aluminium lake, black iron oxide.
Capsule shell (FD & C Blue 2, titanium dioxide, iron oxide red,
iron oxide yellow, gelatin, water, SLS (sodium lauryl sulphate)).
PHARMACODYNAMICS
Mycophenolate mofetil is an immunosuppressive agents.
Mycophenolate mofetil is the 2-morpholinoethyl ester of MPA.
MPA is a potent, selective, uncompetitive and reversible
inhibitor
of
inosine
monophosphate
dehydrogenase,
and
therefore
inhibits
the
_de _
_novo_
pathway
of
guanosine
nucleotide synthesis without incorporation into DNA. Because
T-
and
B-lymphocytes
are
critically
dependent
for
their
proliferation on _ de novo_ synthesis of purines whereas other
cell types can utilise salvage pathways, MPA has more potent
cytostatic effects on lymphocytes than on other cells.
PHARMACOKINETICS
The pharmacokinetics of MMF have been studied in renal,
cardiac and hepatic transplant patients.
In general, the pharmacokinetic profile of MPA is similar in
renal and in cardiac transplant patients. In the early transplant
period, hepatic transplant patients receiving a 1.5g oral MMF
dose or 1g i.v. MMF dose have similar MPA levels compared
to renal transplant patients receiving 1g oral or i.v. MMF.
ABSORPTION
Following oral and intravenous administration, mycophenolate
mofetil